CM
BBIO icon

Caption Management’s BridgeBio Pharma BBIO Stock Holding History

Caption Management’s Portfolio BBIO Stock Details BBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$22.8M Buy
306,400
+81,400
+36% +$5.9M 0.13% 160
2025
Q4 		$17.2M Buy
225,000
+125,000
+125% +$8.21M 0.12% 209
2025
Q3 		$5.19M Sell
100,000
-30,000
-23% -$1.46M 0.04% 477
2025
Q2 		$5.61M Sell
130,000
-116,500
-47% -$4.24M 0.06% 368
2025
Q1 		$8.52M Buy
246,500
+106,500
+76% +$3.59M 0.08% 239
2024
Q4 		$3.84M Sell
140,000
-151,400
-52% -$3.91M 0.04% 460
2024
Q3 		$7.42M Sell
291,400
-233,600
-44% -$6.13M 0.12% 204
2024
Q2 		$13.3M Sell
525,000
-464,000
-47% -$12.7M 0.2% 107
2024
Q1 		$30.6M Buy
989,000
+928,700
+1,540% +$31.6M 0.46% 41
2023
Q4 		$2.43M Sell
60,300
-146,400
-71% -$4.4M 0.03% 562
2023
Q3 		$5.45M Sell
206,700
-1,031,300
-83% -$29.3M 0.08% 294
2023
Q2 		$21.3M Buy
1,238,000
+1,163,000
+1,551% +$17.5M 0.38% 54
2023
Q1 		$1.24M Buy
+75,000
New +$875K 0.02% 577
2022
Q4 		– Sell
-57,500
Closed -$573K – 1287
2022
Q3 		$573K Sell
57,500
-5,000
-8% -$51.9K 0.01% 1037
2022
Q2 		$568K Buy
62,500
+12,500
+25% +$105K 0.01% 1044
2022
Q1 		$507K Sell
50,000
-1,263,400
-96% -$13M 0.01% 1139
2021
Q4 		$21.9M Buy
1,313,400
+1,153,400
+721% +$48.8M 0.25% 82
2021
Q3 		$7.5M Buy
160,000
+77,000
+93% +$4.13M 0.09% 311
2021
Q2 		$5.06M Buy
83,000
+17,000
+26% +$971K 0.07% 361
2021
Q1 		$4.07M Buy
66,000
+33,500
+103% +$2.19M 0.09% 302
2020
Q4 		$2.31M Buy
32,500
+7,500
+30% +$362K 0.05% 403
2020
Q3 		$938K Sell
25,000
-186,500
-88% -$5.87M 0.02% 637
2020
Q2 		$6.9M Buy
211,500
+111,500
+112% +$3.4M 0.23% 116
2020
Q1 		$2.9M Buy
+100,000
New +$3.1M 0.16% 177

Other funds holding BBIO

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
KKRC
Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
DAM
Diamant Asset Management Ridgefield, Connecticut $137B AUM 18.02% 1-Year Est. Return
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Caption Management's BBIO Position: Q1 2026 in Review

Caption Management opened a new position in BridgeBio Pharma (BBIO) in Q1 2026: 431 shares worth $32K. The stake represents ﹤0.01% of the portfolio and ranks #1440 among its holdings. This is a return to the name: Caption Management previously reported a position in BBIO as recently as Q4 2024.

Caption Management first reported a position in BBIO in Q4 2021 and has held it in 9 quarters since. The position peaked at $10.3M in Q2 2024. 457 funds tracked by Wall St. Rank hold BBIO as of Q1 2026.

  • Caption Management held 431 shares of BridgeBio Pharma worth $32K as of Q1 2026.
  • BridgeBio Pharma was a new Caption Management position in Q1 2026.
  • BridgeBio Pharma made up ﹤0.01% of Caption Management's portfolio in Q1 2026, its #1440 holding.
  • Caption Management first reported a position in BridgeBio Pharma in Q4 2021 and has held it in 9 quarters since.
  • Caption Management's BridgeBio Pharma position peaked at $10.3M in Q2 2024.
  • 457 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q1 2026.

Based on Caption Management's 13F filing for Q1 2026, filed 15 May 2026.